MOLECULAR DIAGNOSTIC CODE

The molecular diagnostics (i.e. chromosomal or genetic markers) associated with the brain Tumour during a Cancer Care Spell, taken from the World Health Organisation classification.

National Codes:

1Evidence of IDH1 or IDH2 mutation (Retired 01 April 2017)
2Evidence of methylation of the MGMT gene CpG island (Retired 01 April 2017)
3Evidence of total loss of 1p and 19q (Retired 01 April 2017)
4Evidence of KIAA 1549-BRAF fusion gene (Retired 01 April 2017)
5Other (Retired 01 April 2017)
06Evidence of ALK rearrangement
07Evidence of native ALK
08Evidence of ATRX mutation
09Evidence of wt ATRX
10Evidence of BRAF V600E mutation
11Evidence of wt BRAF
12Evidence of KIAA1549-BRAF fusion
13Evidence of BRAF/RAF1 mutations, or fusions involving genes other than KIAA1549
14Evidence of C11orf95-RELA fusion
15Evidence of native C11orf95 and RELA
16Evidence of amplification or fusion of C19MC locus (chr.19q13.42)
17Evidence of unaltered C19MC locus (chr.19q13.42)
18Evidence of CDK4/6 amplification
19Evidence of CDK4/6 normal copy number
20Evidence of CDKN2A locus homozygous deletion
21Evidence of CDKN2A locus normal copy number
22Evidence of CCND1/2/3 amplification
23Evidence of CCND1/2/3 normal copy number
24Evidence of CTNNB1 mutation
25Evidence of wt CTNNB1
26Evidence of amplification of EGFR
27Evidence of mutation / rearrangement of EGFR
28Evidence of unaltered EGFR
29Evidence of EWSR1-FLI1 fusion
30Evidence of native EWSR1 and FLI1
31Evidence of FGFR1 mutation / rearrangement / fusio
32Evidence of unaltered FGFR1
33Evidence of H3F3A/H3F3B (H3.3) K27M mutation
34Evidence of H3F3A/H3F3B (H3.3) wt K27
35Evidence of H3F3A/H3F3B (H3.3) G34R/V mutation
36Evidence of H3F3A/H3F3B (H3.3) wt G34
37Evidence of HIST1H3B K27M mutation
38Evidence of HIST1H3B wt K27
39Evidence of HIST1H3C K27M mutation
40Evidence of HIST1H3C wt K27
41Evidence of ID2 amplification
42Evidence of ID2 normal copy number
43IDH1 (codon 132) or IDH2 (codon 172) mutation identified
44IDH1 (codon 132) and IDH2 (codon 172) wt confirmed
45Evidence of KLF4 K409Q and TRAF7 mutations
46Evidence of wt KLF4 and TRAF7
47Evidence of MAP2K1 mutation
48Evidence of wt MAP2K1
49Evidence of MET amplification
50Evidence of MET normal copy number
51Evidence of significant MGMT promoter methylation
52Evidence of unmethylated MGMT promoter
53Evidence of MYC/MYCN amplification
54Evidence of MYC/MYCN normal copy number
55Evidence of NF1 biallelic loss / mutation
56Evidence of unaltered NF1
57Evidence of NF2 biallelic loss / mutation
58Evidence of unaltered NF2
59Evidence of NKTR fusions
60Evidence of native NKTR
61Evidence of PTEN biallelic loss / mutation
62Evidence of unaltered PTEN
63Evidence of SDHB or SDHD mutation
64Evidence of wt SDHB and SDHD
65Evidence of SHH pathway activation
66Evidence of normal SHH pathway
67Evidence of inactivation of SMARCB1 (INI1
68Evidence of wt SMARCB1 (INI1)
69Evidence of inactivation of SMARCA4
70Evidence of wt SMARCA4
71Evidence of TERT promotor mutation 7299
72Evidence of wt TERT promotor
73Evidence of TP53 mutation
74Evidence of wt TP53
75Evidence of TSC1 or TSC2 mutation
76Evidence of wt TSC1 and TSC2
77Evidence of VHL mutation
78Evidence of wt VHL gene
79Evidence of WNT pathway activation
80Evidence of normal WNT pathway
81Evidence of WWTR1-CAMTA1 fusion
82Evidence of native WWTR1 and CAMTA1
83Evidence of codeletion of chr.1p and chr.19q
84Evidence of total chr.1p loss but normal copy number of chr.19q
85Evidence of normal copy number of both chr.1p and chr.19q
86Evidence of monosomy chr.6
87Evidence of chr.6 normal copy number
88Evidence of polysomy chr.7
89Evidence of chr.7 normal copy number
90Evidence of loss of chr.10 or chr.10q
91Evidence of chr.10 normal copy number
92Evidence of loss of chr.22 or chr.22q
93Evidence of chr.22 or chr.22q normal copy number
98Other (not listed)
 

This attribute is also known by these names:
ContextAlias
pluralMOLECULAR DIAGNOSTIC CODES

ISO 9001 CERTIFICATION EUROPE